Market Overview

Erbitux 2017-2018 U.S. Promotional Audit Report -


The "Erbitux
2017 U.S. Promotional Audit Report"
report has been added to's

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Erbitux through reportable
    promotional activity in 2017 and how does this compare to its peer set
    in the Colorectal Cancer and Head and Neck Cancer markets?
  • What promotional mix was leveraged (e.g., sales rep detailing,
    physician education, and paid speaking) and what was the median spend
    for each type of activity?
  • How does Eli Lilly's depth of coverage vary within key specialties
    (e.g., Hematology/Oncology, Medical Oncology, Radiation Oncology, and
    Internal Medicine) and how does this compare to its peers and the
    overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Erbitux throughout
    the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for
    Erbitux in 2017?

Data Sources and Methodology:

  • The author leverages company-reported financial transaction data
    disclosed through CMS Open Payments. This data set captures all
    transfers of value (e.g., speaking fees, consulting fees, travel,
    education, and meals) made on behalf of a drug or device manufacturer
    to a physician. More than four years of longitudinal data is available
    - covering payments to more than 975,000 U.S. healthcare professionals.
  • Over 2,700 paid interactions across 1,500 physicians made on behalf of
    Erbitux were carefully examined to support our analysis.

View Comments and Join the Discussion!